相关实验视频

Updated: Jan 9, 2026

Lesion Explorer: A Video-guided, Standardized Protocol for Accurate and Reliable MRI-derived Volumetrics in Alzheimer's Disease and Normal Elderly

Lesion Explorer: A Video-guided, Standardized Protocol for Accurate and Reliable MRI-derived Volumetrics in Alzheimer's Disease and Normal Elderly

Published on: April 14, 2014

在阿尔茨海默氏病连续体中,白色和灰色物质的结构和微结构变化

Lingling Lv¹, Hui Guo¹, Zhiru Zhao¹

¹Department of Neurology, Xianyang Hospital of Yan'an University, Xianyang, Shanxi, China.

Frontiers in aging neuroscience

|December 1, 2025

概括

阿尔茨海默病 (AD) 涉及灰色和白质 (WM) 损失. 白质变性积极促进认知能力下降,提供超越传统措施的新预后标记.

科学领域:

神经成像是一种神经成像.
神经退行性疾病神经退行性疾病
生物标志物开发生物标志物开发

背景情况:

阿尔茨海默病 (AD) 的特点是影响灰质 (GM) 和白质 (WM) 的渐进性脑缩.
了解AD连续体 (临床前,主观认知衰退,MCI,痴呆症) 的体积变化对于诊断和治疗至关重要.

研究的目的:

审查阿尔茨海默病 (AD) 中大脑体积变化的神经成像特征.
探索这些改变在AD连续性的临床影响和预后价值.
提出一个统一的AD神经解剖模型,整合GM和WM病理学.

主要方法:

对神经成像研究的审查,重点关注阿尔茨海默病 (AD) 中的大脑体积变化.
在AD的不同临床阶段对灰质 (GM) 和白质 (WM) 的结构变化的分析.
识别具有预后价值的特定白质 (WM) 区域.

主要成果:

白质量 (WM) 体积损失是阿尔茨海默病 (AD) 临床衰退的积极贡献者,而不仅仅是灰质 (GM) 退化的结果.
特定的白质 (WM) 片段显示缩率,提供超出海马体体积的预后信息.
提出了AD神经解剖学的统一模型,强调了GM和WM病理之间的相互作用.

结论:

白质 (WM) 损失的时空空间模式是阿尔茨海默病 (AD) 进展的重要因素.
对AD神经解剖学的精细理解,整合GM和WM相互作用,对于下一代生物标志物开发至关重要.
人工智能 (AI) 和多omics数据集成对于未来的个性化预测模型至关重要.

关键词:

阿尔茨海默氏症是阿尔茨海默氏症的一种疾病.诊断诊断诊断诊断诊断诊断灰色物质是一种灰色物质.轻度的认知障碍轻度的认知障碍白质是白色物质的组成部分.

更多相关视频

Abbiategrasso Brain Bank Protocol for Collecting, Processing and Characterizing Aging Brains

Abbiategrasso Brain Bank Protocol for Collecting, Processing and Characterizing Aging Brains

Published on: June 3, 2020

Whole-brain Segmentation and Change-point Analysis of Anatomical Brain MRI—Application in Premanifest Huntington's Disease

Whole-brain Segmentation and Change-point Analysis of Anatomical Brain MRI—Application in Premanifest Huntington's Disease

Published on: June 9, 2018

相关概念视频

Alzheimer's Disease: Overview

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...

Dementia

Dementia

Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....

Alzheimer's Disease: Treatment

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...

Cognitive Development During Adulthood

Cognitive Development During Adulthood

Cognitive development continues throughout adulthood, undergoing significant shifts across early, middle, and late stages. Individual transition occurs from adolescent idealism to pragmatic and adaptable thinking in early adulthood. During this period, individuals learn to integrate personal beliefs with the recognition that other perspectives are equally valid. Exposure to the complexities of modern society, diverse experiences, and higher education contribute to this adaptive thought process,...